Somerset, N.J. – January 21, 2016 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced the appointment of Sally Langa to the position of Vice President, Business Development, for Catalent’s Development and Analytical Services offerings. In this role, Ms. Langa will be responsible for growing Catalent’s early phase development business for small molecule compounds, including analytical services, formulation development, and micronization.
Ms. Langa joins Catalent from Halo Pharma where she held the role of Vice President, Sales and Marketing. Her career within the pharmaceutical services industry, which spans almost thirty years, has also seen her hold a number of senior positions at Patheon.
“Sally brings a huge amount of experience to Catalent and will be a pivotal part of the team charged with meeting the company’s ambitious growth targets,” commented Jonathan Arnold, Vice President and General Manager of Advanced Delivery Technologies. “Catalent sees great growth potential in its early stage development activities, as well as continued opportunity to integrate these services further into the clinical and commercial phases of development.”
Ms. Langa is an active member of the Drug, Chemical and Associated Technologies (DCAT) Association, and is currently on the Technology Committee. She is also a Trustee on the Board of the Pharma & Biopharma Outsourcing Association (PBOA).
Catalent’s Development and Analytical services, located at sites throughout the US and Europe, offer global solutions with specialty handling capabilities for controlled substances, highly potent, cytotoxic, and temperature critical compounds, to handle the most challenging molecules.
+44 (0)7580 041073
+44 (0) 161 728 5880
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and global clinical supply services. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com